Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.58 |
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412630 | 0.90 | ROCK2 (0.64) | MAOBMAOAROCK2ROCK1POLB | |
| SCHEMBL5413303 | 0.87 | MAOB (0.59) | MAOBMAOAROCK2ROCK1POLB | |
| SCHEMBL5414851 | 0.82 | ROCK2 (0.58) | MAOBMAOAROCK2ROCK1POLB | |
| SCHEMBL5413451 | 0.82 | MAPT (0.62) | MAOBMAOAROCK2ROCK1NPC1 | |
| SCHEMBL5409039 | 0.80 | MAPT (0.60) | MAOBROCK2ROCK1TP53MAPT | |
| SCHEMBL5419152 | 0.80 | MAOB (0.67) | MAOBMAOAROCK2MEN1KMT2A | |
| SCHEMBL5419581 | 0.79 | ROCK2 (0.62) | MAOBROCK2ROCK1MEN1KMT2A | |
| SCHEMBL5418304 | 0.79 | ROCK2 (0.83) | MAOBROCK2ROCK1NPC1RAB9A | |
| SCHEMBL5413661 | 0.78 | MAOB (0.56) | MAOBROCK2ROCK1NPC1RAB9A | |
| SCHEMBL5418918 | 0.78 | MAOB (0.58) | MAOBROCK2ROCK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | MAOB 2025/4885MAOA 2003/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.